Related Experiment Video
Updated: Jun 20, 2025
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
Morvan's syndrome with hypercoagulable condition in a patient positive for anti-CASPR2 antibodies: A case report
Xintong Pang1, Yanming Li1, Zining Liu1
1Department of Laboratory Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Rationale:
The phenomenon of hypercoagulability has not been previously documented in individuals with Morvan's syndrome, especially in those associated with contactin-associated protein-like receptor 2 (CASPR2).
Patient Concerns:
A previously healthy 32-year-old Chinese male was admitted to the hospital with central and peripheral neurologic symptoms. The patient was tested positive for anti-CASPR2 antibodies, and also presented with an activated coagulation state on admission, characterized by a low activated partial thromboplastin time and a high platelet count. With gradual improvement of clinical symptoms, activated partial thromboplastin time, and platelet count returned to normal. Simultaneously, anti-CASPR2 antibody titers significantly decreased and eventually became undetectable.
Diagnoses:
The patient was diagnosed as Morvan's syndrome with positive anti-CASPAR2 antibodies accompanied with hypercoagulable state.
Interventions:
Plasmapheresis was administered to improve the symptoms combined with prednisolone acetate therapy.
Outcomes:
The patient experienced complete resolution of all symptoms during hospitalization and generally recovery after 2 months of discharge.
Lessons:
Emphasis should be directed towards hypercoagulability in individuals diagnosed with Morvan's syndrome, particularly those presenting with positive anti-CASPR2 antibodies. Anticoagulant therapy may represent a novel therapeutic approach for individuals afflicted with Morvan's syndrome and exhibiting positivity for anti-CASPR2 antibodies.
